抗凝治疗在肝硬化患者脾切除术后减少PVT的疗效及安全性研究

肝脏 ›› 2022, Vol. 27 ›› Issue (2): 169-173.

抗凝治疗在肝硬化患者脾切除术后减少PVT的疗效及安全性研究

甄勇, 王兵济, 杜华劲, 高学健, 王仔平, 宣佶, 张尊庶, 王传泰, 耿家宝

239000 安徽滁州市第一人民医院普外科(甄勇,杜华劲,高学健,王仔平,张尊庶,王传泰);东部战区总医院秦淮医疗区肝胆外科(王兵济),胃镜中心(宣佶),感染科/肝病中心(耿家宝)

收稿日期:2021-04-18 出版日期:2022-02-28 发布日期:2022-04-19
通讯作者: 耿家宝,Email:gengjiabao666@126.com
基金资助:
国家自然科学青年基金(81704196)

Efficacy and safety of anticoagulation therapy for PVT after splenectomy in patients with liver cirrhosis

ZHEN Yong¹, WANG Bing-ji², DU Hua-jin¹, GAO Xue-jian¹, WANG Zi-ping¹, XUAN Ji³, ZHANG Zun-shu¹, WANG Chuan-tai¹, GENG Jia-bao⁴

1. Department of General Surgery, Chuzhou First People's Hospital, Anhui 239000, China;
2. Department of General Surgery, Eastern Theater General Hospital QinHuai District Medical Area, Nanjing 210002, China;
3. Department of Endoscopy center, Eastern Theater General Hospital QinHuai District Medical Area, Nanjing 210002,China;
4. Department of Infectious Diseases, Eastern Theater General Hospital Qinhuai District Medical Area, Nanjing 210002, China

Received:2021-04-18 Online:2022-02-28 Published:2022-04-19
Contact: GENG Jia-bao, Email: gengjiabao666@126.com

摘要/Abstract

摘要： 目的探讨抗凝治疗在肝硬化患者行脾脏切除术后,减少门静脉系统血栓(PVT)发生风险的疗效及安全性。方法选择2015年12月至2020年6月在滁州市第一人民医、东部战区总医院秦淮医疗区住院行脾脏切除术的肝硬化患者106例,对照组50例,试验组56例。试验组患者术后24 h,给予低分子量肝素(皮下注射,1次/日,1周)联合华法林(口服,24周)抗凝治疗。对照组未予抗凝治疗。比较两组患者术后PVT发生率、肝功指标、Child-Pugh评分、门静脉直径、门静脉血流速度、并发症发生率、平均住院时间等。结果抗凝组、对照组术后PVT发生率分别为2周16.1%和44%,4周12.5%和40%,12周8.9%和38.0%,24周7.1%和34.0%,48周7.1%和32.0%。术后2周、4周、12周、24周、48周抗凝组的TBil、DBil、ALT、Child-Pugh评分均低于对照组, P<0.05。术后2周、4周、12周、24周、48周抗凝组的门静脉平均直径小于对照组,血流速度高于对照组,P<0.05。术后48周试验组、对照组并发症的发生率分别为:消化道出血3.6%、10.0%,肝性脑病1.8%、8.0%,肠坏死1.8%、6.0%,P>0.05;腹水14.3%、32.0%,P<0.05。抗凝组平均住院时间(10.8±2.9)d,小于对照组[(15.9±4.6)d],P<0.05。抗凝治疗期间,未见明显不良反应。结论抗凝治疗可有效减少肝硬化患者脾切术后PVT的发生风险,安全性良好。

关键词: 肝硬化, 脾切除, 抗凝治疗, 门静脉系统血栓, 安全性

Abstract: Objective To investigate the efficacy and safety of anticoagulation therapy for portal vein thrombosis (PVT) after splenectomy in cirrhosis patients. Methods A total of 106 cirrhosis patients admitted to our hospital from December 2015 to June 2019 who underwent splenectomy were enrolled. They were randomly divided into control group (50 cases) and experimental group (56 cases). Patients in experimental group were treated with low molecular heparin (subcutaneous injection, once a day for a week) combined with warfarin (oral administration, 24 weeks) 24 hours after splenectomy, while the control group received no anticoagulation therapy after splenectomy. The rate of PVT, liver function index, Child-Pugh score, diameter of portal vein (Dpv), velocity of portal vein (Vpv), complication rates and average hospitalization time of 2 groups were compared. Results The rates of PVT in experimental group and control group were 16.1% and 44% in 2 weeks after splenectomy, 12.5% and 40.0% in 4 weeks after splenectomy, 8.9% and 38.0% in 12 weeks after splenectomy, 7.1% and 34.0% in 24 weeks after splenectomy, 7.1% and 32.0% in 48 weeks after splenectomy, respectively. The levels of total bilirubin (TBil), direct bilirubin (DBil), alanine aminotransferase (ALT) and Child-Pugh score of experimental group in week 2, 4, 12, 24 and 48 after splenectomy were significantly lower than those of control group (P<0.05), respectively. The Dpv of experimental group was wider than that of control group, and the Vpv of experimental group was faster than that of control group in week 2, 4, 12, 24 and 48, P<0.05. At week 48, the rates of alimentary tract hemorrhage of experimental group and control group were 3.6% and 10.0% (P>0.05), the rates of hepatic encephalopathy of the 2 groups were1.8% and 8.0% (P>0.05), the rates of intestinal necrosis of the 2 groups were 1.8% and 6.0% (P>0.05), the rates of ascites of the 2 groups were 14.3% and 32.0% (P<0.05). The average hospitalization time of experimental group (10.8 ± 2.9 days) was significantly shorter than that of control group (15.9 ± 4.6 days), P<0.05. No obvious adverse reaction was observed during the period of anticoagulation therapy. Conclusion Anticoagulation therapy can effectively reduce PVT risk after splenectomy in cirrhosis patients, with satisfactory safety.

Key words: Liver cirrhosis, Splenectomy, Anticoagulation therapy, Portal vein thrombosis, Safety

甄勇, 王兵济, 杜华劲, 高学健, 王仔平, 宣佶, 张尊庶, 王传泰, 耿家宝. 抗凝治疗在肝硬化患者脾切除术后减少PVT的疗效及安全性研究[J]. 肝脏, 2022, 27(2): 169-173.

ZHEN Yong, WANG Bing-ji, DU Hua-jin, GAO Xue-jian, WANG Zi-ping, XUAN Ji, ZHANG Zun-shu, WANG Chuan-tai, GENG Jia-bao. Efficacy and safety of anticoagulation therapy for PVT after splenectomy in patients with liver cirrhosis[J]. Chinese Hepatolgy, 2022, 27(2): 169-173.

参考文献

[1] Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol, 2009, 51: 682-689.
[2] Fimognari FL, De Santis A, Piccheri C, et a1. Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis.J Lab Clin Med, 2005, 146: 238-243.
[3] Maruyama H, Okugawa H, Takahashi M, et a1.De novo portal vein thrombosis in virus-related cirrhosis:predictive factors and long-term outcomes. Am J Gastroenterol, 2013, 108:568-574.
[4] 张鹰,李志伟,赵新,等. 脾切除贲门周围血管离断术后患者门静脉系统血栓形成及肝功能评分. 中华肝胆外科杂志,2018,24:446-449.
[5] Tripodi A, Primignani M, Lemma L, et al. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol, 2013, 59: 265-270.
[6] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志,2019,27:846-865.
[7] 李相文,涂明利. 早期应用低分子肝素预防腹腔镜脾切除食管胃底静脉断流术后门静脉血栓形成临床研究. 实用肝脏病杂志,2017,20:179-182.
[8] Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology, 2017, 153: 480-487.
[9] 王泉雄,方志杰,刘志苏,等. 腹腔镜脾切除后门静脉系统血栓形成早期预防与治疗. 腹部外科,2019,32:270-273.
[10] 赵晓飞,林栋栋, 李宁,等. 脾切除联合食管胃底曲张静脉断流术后应用华法林对门静脉血栓的防治作用. 实用肝脏病杂志,2019,22:240-243.
[11] D'Amico G,De FR.Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology, 2003, 38: 599-612.
[12] Delgado MG,Seijo S,Yepes I,et a1. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol, 2012, 10: 776-783.
[13] Qi X, De Stefano V, Li H, et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med, 2015, 26: 23-29.
[14] Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology, 2017, 53: 480-487.
[15] Loudin M, Ahn J. Portal vein thrombosis in cirrhosis. J Clin Gastroenterol, 2017, 51: 579-585.
[16] 游玉峰,谭必勇,何小俊,等. PTIPS治疗脾切除术后并发门静脉血栓形成的门静脉高压症患者安全性和效果分析. 实用肝脏病杂志,2018,21,372-375.
[17] 禹亚彬,宋研,陈亚,等. 腹腔镜脾切除术后抗凝治疗预防门静脉系统血栓的Meta分析. 中华肝胆外科杂志,2018,24:333-335.